ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Purc...
September 20 2019 - 4:05PM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system (CNS) disorders, today announced the closing of its
previously announced underwritten public offering of 7,187,500
shares of its common stock, which includes 937,500 shares of common
stock sold pursuant to the underwriters’ full exercise of their
option to purchase additional shares, at a public offering price of
$40.00 per share. The gross proceeds from the offering to ACADIA,
before deducting underwriting discounts and commissions and other
estimated offering expenses payable by ACADIA, are approximately
$287.5 million.
BofA Merrill Lynch and J.P. Morgan Securities LLC acted as the
joint book-running managers for the offering. Cowen and SVB Leerink
acted as co-lead managers and Cantor Fitzgerald & Co.,
Canaccord Genuity, JMP Securities and Needham & Company acted
as co-managers for the offering.
The shares of common stock described above were offered by
ACADIA pursuant to a shelf registration statement filed by ACADIA
with the Securities and Exchange Commission (SEC) that became
automatically effective on November 26, 2018. A final prospectus
supplement and accompanying prospectus related to the offering was
filed with the SEC and is available on the SEC’s website located at
http://www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus related to this offering may be
obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College
Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus
Department, Email: dg.prospectus_requests@baml.com, or from J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866)
803-9204, or by email to: prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has
developed and commercialized the first and only medicine approved
for the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. ACADIA also has ongoing clinical
development efforts in additional areas with significant unmet
need, including dementia-related psychosis, major depressive
disorder, the negative symptoms of schizophrenia, and Rett
syndrome.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190920005481/en/
Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Media Contact: ACADIA Pharmaceuticals Inc. Maurissa Messier
(858) 768-6068 media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024